User:RelentlessRecusant/VyThera

VyThera is the marketed name for the Acumen Science Laboratories vaccine against HIV-1.

The vaccine itself consists of recombinant viral proteins and B cell activation & proliferation factors, a novel dually-pronged approach to HIV vaccination. The first fraction of the vaccine includes purified N-terminus peptide from human recombinant major histocompatbility complex 2 (MHC2), interleukin-6 (IL-6), colony stimulating factors 1-3, protein interactants and cytokines known to induce B-cell activation and plasma cell proliferation. This hyperexcited state allows B-cells to be activated with faster temporal kinetics, and host B-cells are immunized with the second fraction, which is a mixture of HIV-1 viral peptides produced in an in vitro human recombinant system, including Vif. This system of immunization, which is used in research in other species to produce high titers of highly specific antibody, leads to the production of hα-Vif and other host antibodies. hα-Vif in particular inhibits viral Vif protein activity, leading to somatic hypermutation of the viral genome by host cytidine deaminases such as APOBEC3G and negation of viral replication. Eventually, within several months — years, the high antibody titers are capable of diffusing into cytoplasms and nuclei of infected cells, targeting assembling HIV particles and preventing further downstream infectivity. This leads to the gradual and slow recovery of CD4 T-cell titers.